{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:14:08Z","timestamp":1793780048209,"version":"4.6.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41588-024-01747-1","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:02:06Z","timestamp":1715925726000},"page":"1121-1133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-9592","authenticated-orcid":false,"given":"Calixto-Hope G.","family":"Lucas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-7059","authenticated-orcid":false,"given":"Kanish","family":"Mirchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyounghee","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-9708","authenticated-orcid":false,"given":"Hinda","family":"Najem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-5853","authenticated-orcid":false,"given":"William C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Zakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-6397","authenticated-orcid":false,"given":"Kyla","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte D.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha A.","family":"Cady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-2457","authenticated-orcid":false,"given":"Abrar","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-0191","authenticated-orcid":false,"given":"S. John","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-8120","authenticated-orcid":false,"given":"Joanna J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Magill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-9992","authenticated-orcid":false,"given":"Craig M.","family":"Horbinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-7999","authenticated-orcid":false,"given":"David A.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8300-7261","authenticated-orcid":false,"given":"Arie","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9633-1100","authenticated-orcid":false,"given":"Harish N.","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-8695","authenticated-orcid":false,"given":"Amy B.","family":"Heimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-8864","authenticated-orcid":false,"given":"David R.","family":"Raleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"1747_CR1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro. Oncol. 24, v1\u2013v95 (2022).","journal-title":"Neuro. Oncol."},{"key":"1747_CR2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner, R. et al. EANO guideline on the diagnosis and management of meningiomas. Neuro. Oncol. 23, 1821\u20131834 (2021).","journal-title":"Neuro. Oncol."},{"key":"1747_CR3","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1002\/cam4.2516","volume":"8","author":"D Lin","year":"2019","unstructured":"Lin, D. et al. Trends in intracranial meningioma incidence in the United States, 2004\u20102015. Cancer Med. 8, 6458\u20136467 (2019).","journal-title":"Cancer Med."},{"key":"1747_CR4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm, F. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 18, 682\u2013694 (2017).","journal-title":"Lancet Oncol."},{"key":"1747_CR5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","volume":"133","author":"A Olar","year":"2017","unstructured":"Olar, A. et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol. 133, 431\u2013444 (2017).","journal-title":"Acta Neuropathol."},{"key":"1747_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury, A. et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat. Genet. 54, 649\u2013659 (2022).","journal-title":"Nat. Genet."},{"key":"1747_CR7","doi-asserted-by":"crossref","first-page":"21715","DOI":"10.1073\/pnas.1912858116","volume":"116","author":"AJ Patel","year":"2019","unstructured":"Patel, A. J. et al. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc. Natl Acad. Sci. USA 116, 21715\u201321726 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1747_CR8","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noab213","volume":"24","author":"J Driver","year":"2021","unstructured":"Driver, J. et al. A molecularly integrated grade for meningioma. Neuro. Oncol. 24, 796\u2013808 (2021).","journal-title":"Neuro. Oncol."},{"key":"1747_CR9","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","volume":"39","author":"SLN Maas","year":"2021","unstructured":"Maas, S. L. N. et al. Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated. J. Clin. Oncol. 39, 3839\u20133852 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1747_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri, F. et al. A clinically applicable integrative molecular classification of meningiomas. Nature 597, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"1747_CR11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/neuonc\/noac224","volume":"25","author":"A Choudhury","year":"2022","unstructured":"Choudhury, A. et al. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro. Oncol. 25, 520\u2013530 (2022).","journal-title":"Neuro. Oncol."},{"key":"1747_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00401-022-02455-y","volume":"144","author":"HN Vasudevan","year":"2022","unstructured":"Vasudevan, H. N. et al. Intratumor and informatic heterogeneity influence meningioma molecular classification. Acta Neuropathol. 144, 579\u2013583 (2022).","journal-title":"Acta Neuropathol."},{"key":"1747_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18582-7","volume":"11","author":"ST Magill","year":"2020","unstructured":"Magill, S. T. et al. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat. Commun. 11, 1\u201315 (2020).","journal-title":"Nat. Commun."},{"key":"1747_CR14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro. Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro. Oncol."},{"key":"1747_CR15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-022-04171-9","volume":"160","author":"WC Chen","year":"2022","unstructured":"Chen, W. C. et al. Radiotherapy for meningiomas. J. Neurooncol. 160, 505\u2013515 (2022).","journal-title":"J. Neurooncol."},{"key":"1747_CR16","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","volume":"21","author":"PK Brastianos","year":"2019","unstructured":"Brastianos, P. K. et al. Advances in multidisciplinary therapy for meningiomas. Neuro. Oncol. 21, i18\u2013i31 (2019).","journal-title":"Neuro. Oncol."},{"key":"1747_CR17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-010-0349-8","volume":"99","author":"PY Wen","year":"2010","unstructured":"Wen, P. Y., Quant, E., Drappatz, J., Beroukhim, R. & Norden, A. D. Medical therapies for meningiomas. J. Neurooncol. 99, 365\u2013378 (2010).","journal-title":"J. Neurooncol."},{"key":"1747_CR18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/neuonc\/noab243","volume":"24","author":"M Preusser","year":"2021","unstructured":"Preusser, M. et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro. Oncol. 24, 755\u2013767 (2021).","journal-title":"Neuro. Oncol."},{"key":"1747_CR19","first-page":"101","volume":"24","author":"WL Bi","year":"2021","unstructured":"Bi, W. L. et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results. Neuro. Oncol. 24, 101\u2013113 (2021).","journal-title":"Neuro. Oncol."},{"key":"1747_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29052-7","volume":"13","author":"PK Brastianos","year":"2022","unstructured":"Brastianos, P. K. et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat. Commun. 13, 1325 (2022).","journal-title":"Nat. Commun."},{"key":"1747_CR21","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","volume":"29","author":"WC Chen","year":"2023","unstructured":"Chen, W. C. et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat. Med. 29, 3067\u20133076 (2023).","journal-title":"Nat. Med."},{"key":"1747_CR22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"LA Gilbert","year":"2014","unstructured":"Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647\u2013661 (2014).","journal-title":"Cell"},{"key":"1747_CR23","first-page":"699","volume":"9","author":"CN Kline","year":"2016","unstructured":"Kline, C. N. et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro. Oncol. 9, 699\u2013709 (2016).","journal-title":"Neuro. Oncol."},{"key":"1747_CR24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3171\/2019.8.JNS191266","volume":"133","author":"MW Youngblood","year":"2019","unstructured":"Youngblood, M. W. et al. Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J. Neurosurg. 133, 1345\u20131354 (2019).","journal-title":"J. Neurosurg."},{"key":"1747_CR25","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","volume":"108","author":"F Sahm","year":"2016","unstructured":"Sahm, F. et al. TERT promoter mutations and risk of recurrence in meningioma. J. Natl Cancer Inst. 108, djv377 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"1747_CR26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11060-019-03333-6","volume":"145","author":"A Guyot","year":"2019","unstructured":"Guyot, A. et al. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma. J. Neurooncol. 145, 449\u2013459 (2019).","journal-title":"J. Neurooncol."},{"key":"1747_CR27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","volume":"23","author":"MW Youngblood","year":"2021","unstructured":"Youngblood, M. W. et al. Associations of meningioma molecular subgroup and tumor recurrence. Neuro. Oncol. 23, 783\u2013794 (2021).","journal-title":"Neuro. Oncol."},{"key":"1747_CR28","first-page":"443","volume":"130","author":"WC Chen","year":"2018","unstructured":"Chen, W. C. et al. Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. J. Neurosurg. 130, 443\u2013450 (2018).","journal-title":"J. Neurosurg."},{"key":"1747_CR29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00401-023-02544-6","volume":"145","author":"V Tang","year":"2023","unstructured":"Tang, V. et al. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas. Acta Neuropathol. 145, 497\u2013500 (2023).","journal-title":"Acta Neuropathol."},{"key":"1747_CR30","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00401-018-1844-9","volume":"135","author":"LM Katz","year":"2018","unstructured":"Katz, L. M. et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 135, 955\u2013963 (2018).","journal-title":"Acta Neuropathol."},{"key":"1747_CR31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell 40, 639\u2013655.e13 (2022).","journal-title":"Cancer Cell"},{"key":"1747_CR32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"1747_CR33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0012-1606(87)90118-7","volume":"120","author":"GF Couly","year":"1987","unstructured":"Couly, G. F. & Douarin, N. M. L. Mapping of the early neural primordium in quail-chick chimeras: II. The prosencephalic neural plate and neural folds: implications for the genesis of cephalic human congenital abnormalities. Dev. Biol. 120, 198\u2013214 (1987).","journal-title":"Dev. Biol."},{"key":"1747_CR34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1242\/dev.105445","volume":"142","author":"M Sim\u00f5es-Costa","year":"2015","unstructured":"Sim\u00f5es-Costa, M. & Bronner, M. E. Establishing neural crest identity: a gene regulatory recipe. Development 142, 242\u2013257 (2015).","journal-title":"Development"},{"key":"1747_CR35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt, C. R. et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat. Biotechnol. 38, 586\u2013599 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1747_CR36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/neuonc\/nox094","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar, G. M. et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro. Oncol. 19, 535\u2013545 (2017).","journal-title":"Neuro. Oncol."},{"key":"1747_CR37","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1016\/j.celrep.2018.03.013","volume":"22","author":"HN Vasudevan","year":"2018","unstructured":"Vasudevan, H. N. et al. Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. Cell Rep. 22, 3672\u20133683 (2018).","journal-title":"Cell Rep."},{"key":"1747_CR38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48846-2","volume":"9","author":"A Mangelinck","year":"2019","unstructured":"Mangelinck, A. et al. MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma. Sci. Rep. 9, 12301 (2019).","journal-title":"Sci. Rep."},{"key":"1747_CR39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75807-x","volume":"10","author":"S Borchert","year":"2020","unstructured":"Borchert, S. et al. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma. Sci. Rep. 10, 18677 (2020).","journal-title":"Sci. Rep."},{"key":"1747_CR40","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"1747_CR41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-05023-2","volume":"608","author":"A Erickson","year":"2022","unstructured":"Erickson, A. et al. Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature 608, 360\u2013367 (2022).","journal-title":"Nature"},{"key":"1747_CR42","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"LB Nabors","year":"2020","unstructured":"Nabors, L. B. et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 18, 1537\u20131570 (2020).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"1747_CR43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.wneu.2017.03.009","volume":"102","author":"Almeida","year":"2017","unstructured":"Almeida et al. Clinical outcome, tumor recurrence, and causes of death: a long-term follow-up of surgically treated meningiomas. World Neurosurg. 102, 139\u2013143 (2017).","journal-title":"World Neurosurg."},{"key":"1747_CR44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00401-015-1459-3","volume":"130","author":"JR Menke","year":"2015","unstructured":"Menke, J. R. et al. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol. 130, 441\u2013443 (2015).","journal-title":"Acta Neuropathol."},{"key":"1747_CR45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449\u2013462 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR46","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR47","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR48","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR49","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR50","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMcps1407030","volume":"373","author":"L James","year":"2015","unstructured":"James, L. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR52","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"R Caroline","year":"2015","unstructured":"Caroline, R. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/acel.12479","volume":"15","author":"AE Webb","year":"2016","unstructured":"Webb, A. E., Kundaje, A. & Brunet, A. Characterization of the direct targets of FOXO transcription factors throughout evolution. Aging Cell 15, 673\u2013685 (2016).","journal-title":"Aging Cell"},{"key":"1747_CR54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68177-x","volume":"10","author":"MV Corniola","year":"2020","unstructured":"Corniola, M. V., Lem\u00e9e, J.-M. & Meling, T. R. Histological transformation in recurrent WHO grade I meningiomas. Sci. Rep. 10, 11220 (2020).","journal-title":"Sci. Rep."},{"key":"1747_CR55","first-page":"vdaa129","volume":"2","author":"S Nakasu","year":"2020","unstructured":"Nakasu, S., Notsu, A., Na, K. & Nakasu, Y. Malignant transformation of WHO grade I meningiomas after surgery or radiosurgery: systematic review and meta-analysis of observational studies. Neurooncol. Adv. 2, vdaa129 (2020).","journal-title":"Neurooncol. Adv."},{"key":"1747_CR56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-018-2813-9","volume":"138","author":"WC Chen","year":"2018","unstructured":"Chen, W. C. et al. Salvage therapy outcomes for atypical meningioma. J. Neurooncol. 138, 425\u2013433 (2018).","journal-title":"J. Neurooncol."},{"key":"1747_CR57","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnen\/nlaa038","volume":"79","author":"G Gauchotte","year":"2020","unstructured":"Gauchotte, G. et al. Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study. J. Neuropathol. Exp. Neurol. 79, 754\u2013762 (2020).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1747_CR58","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.3590","volume":"48","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768\u2013776 (2016).","journal-title":"Nat. Genet."},{"key":"1747_CR59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.3984","volume":"22","author":"N Andor","year":"2016","unstructured":"Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22, 105\u2013113 (2016).","journal-title":"Nat. Med."},{"key":"1747_CR60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","volume":"578","author":"M Gerstung","year":"2020","unstructured":"Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122\u2013128 (2020).","journal-title":"Nature"},{"key":"1747_CR61","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani, M. et al. Tracking the evolution of non\u2013small-cell lung cancer. N. Engl. J. Med. 376, 2109\u20132121 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1747_CR62","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nat. Cancer 3, 1534\u20131552 (2022).","journal-title":"Nat. Cancer"},{"key":"1747_CR63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1227\/00006123-199009000-00008","volume":"27","author":"WH Lee","year":"1990","unstructured":"Lee, W. H. Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery 27, 389\u2013395; discussion 396 (1990).","journal-title":"Neurosurgery"},{"key":"1747_CR64","doi-asserted-by":"crossref","first-page":"e0178322","DOI":"10.1371\/journal.pone.0178322","volume":"12","author":"Y Mei","year":"2017","unstructured":"Mei, Y. et al. Genomic profile of human meningioma cell lines. PLoS ONE 12, e0178322 (2017).","journal-title":"PLoS ONE"},{"key":"1747_CR65","first-page":"e123","volume":"46","author":"W Zhou","year":"2018","unstructured":"Zhou, W., Triche, T. J., Laird, P. W. & Shen, H. SeSAMe: reducing artifactual detection of DNA methylation by Infinium BeadChips in genomic deletions. Nucleic Acids Res. 46, e123 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1747_CR66","doi-asserted-by":"publisher","unstructured":"Mdm247. Mdm247\/spatial_meningioma: v_1.0.0. Zenodo https:\/\/doi.org\/10.5281\/zenodo.10927737 (2024).","DOI":"10.5281\/zenodo.10927737"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-024-01747-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-024-01747-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-024-01747-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:35:56Z","timestamp":1721385356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-024-01747-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1747"],"URL":"https:\/\/doi.org\/10.1038\/s41588-024-01747-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2921804\/v1","asserted-by":"object"}]},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}